Abstract This article traces the shifting fortunes of for-profit psychedelic medicine through two phases: a boom from 2016 to late 2021, followed by a bust that continued through late 2024. It argues that the forces driving this cycle are best understood through the concept of capitalization, which links present valuations to investor expectations about future […]
Continue Reading
Originally published at sbhager.com Sandy Brian Hager Reading in the latest FT Weekend about NovoNordisk’s recent moves to corner the market for weight loss drugs, I was reminded of an eye-opening article from Rana Foroohar late last year. In that piece, the always-sharp Foroohar discusses the emergence of new blockbuster drugs known as semaglutides. These […]
Continue Reading
Originally published at pluralistic.net Cory Doctorow Comparing the government to a household or a business isn’t merely inapt (a government is a currency creator, while a household is a currency user – their budgeting constraints are totally unrelated) – it’s also profoundly dishonest. Like, if you really are worried about government “living beyond its means,” […]
Continue Reading
DT Cochrane Harvard Medical School researchers Michelle Holmes and Wendy Chen wrote an op-ed in the New York Times about research they published in 2010 that found aspirin may be an effective treatment for breast cancer patients. The op-ed was not just calling attention to these results. Rather, it was a complaint that the research […]
Continue Reading